Managing post-PRK discomfort

Article

When treating post-phacorefractive keratectomy (PRK) discomfort, there are no significant differences in either safety or efficacy between bromfenac twice-daily and ketorolac four times daily, according to a study published in the February issue of the Journal of Refractive Surgery.

When treating post-phacorefractive keratectomy (PRK) discomfort, there are no significant differences in either safety or efficacy between bromfenac twice-daily and ketorolac four times daily, according to a study published in the February issue of the Journal of Refractive Surgery.

Neal A. Sher, MD, FACS - of the Department of Ophthalmology at the University of Minnesota Medical School, Minneapolis, US - and colleagues compared the two NSAIDs in terms of post-PRK prevention of pain, foreign body sensation, burning and light sensitivity, as well as epithelial healing rates by randomizing eyes (n=212) to receive one of the anti-inflammatories (bromfenac, n=105; ketorolac, n=107) in an open label trial. Any patient having two eyes treated received both medications, one for each eye. All eyes underwent PRK with the same technique, and were then fitted with the Acuvue Oasys bandage contact lens (Johnson & Johnson Vision Care) before receiving either bromfenac or ketorolac. Postoperatively, patients also received BSS, prednisolone acetate 1.0%, gatifloxacin ophthalmic solution 0.3% and, for some patients, mitomycin C 0.02%.

The drugs had similar epithelial healing rates, and neither was associated with a drug-related adverse event. Between the two drug populations, the research team did not note any significant differences in postoperative pain, burning, foreign body sensation or photophobia.

The team concluded that, following the usual post-PRK safety measures including application of cold BSS and use of a bandage contact lens, there are no differences in discomfort reduction between bromfenac twice daily and ketorolac four times daily.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.